Stocks and Investing Stocks and Investing
Wed, August 9, 2023
Tue, August 8, 2023

Charles Duncan Maintained (STOK) at Buy with Decreased Target to $14 on, Aug 8th, 2023


Published on 2024-10-28 05:40:47 - WOPRAI, Charles Duncan
  Print publication without navigation


Charles Duncan of Cantor Fitzgerald, Maintained "Stoke Therapeutics, Inc." (STOK) at Buy with Decreased Target from $18 to $14 on, Aug 8th, 2023.

Charles has made no other calls on STOK in the last 4 months.



There are 3 other peers that have a rating on STOK. Out of the 3 peers that are also analyzing STOK, 1 agrees with Charles's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Greg Harrison of "B of A Securities" Upgraded from Sell to Hold and Increased Target to $12 on, Monday, May 1st, 2023


These are the ratings of the 2 analyists that currently disagree with Charles


  • Joseph Stringer of "Needham" Reiterated at Strong Buy and Held Target at $25 on, Monday, August 7th, 2023
  • Sumant Kulkarni of "Canaccord Genuity" Initiated at Strong Buy and Held Target at $24 on, Wednesday, April 26th, 2023